5-Fluorouracil Treatment of Problematic Scars
- 1 January 2009
- journal article
- reconstructive
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 123 (1) , 139-148
- https://doi.org/10.1097/prs.0b013e3181904d1b
Abstract
Background: Keloids and hypertrophic scars can be uncomfortable, disfiguring, and aesthetically undesirable. Anecdotal reports suggest that low-dose intralesional fluorouracil can be used to treat these undesirable scars. Methods: Using a prospective case series protocol, both keloid and hypertrophic scar patients were included. Keloid patients underwent excision followed by a series of treatments with intralesional 5-fluorouracil into the healing scar to prevent recurrence (n = 32). The hypertrophic scar patients were treated with the same series of injections without scar excision to both control symptoms and improve scar appearance (n = 21). The primary outcome measures were scar volume and a symptom questionnaire. Patients were followed for 1 year after completing the injection treatments. Results: In the keloid group, the recurrence rate was 19 percent at 1-year follow-up for this group of patients who had failed previous corticosteroid injection therapy. In the hypertrophic scar group, 14 percent did not respond to the series of injections. In this group, there was a median volume decrease of 50 percent maintained for 1 year after injection therapy was terminated. Conclusions: Intralesional fluorouracil is a safe and effective means of controlling problem scars in terms of both recurrence and symptom control. Benefits were maintained for at least 1 year after completion of therapy. Intralesional 5-fluorouracil should be considered another option for patients suffering from problematic scars.Keywords
This publication has 42 references indexed in Scilit:
- Gene Profiling of Keloid Fibroblasts Shows Altered Expression in Multiple Fibrosis-Associated PathwaysJournal of Investigative Dermatology, 2008
- Increased CCN2 Transcription in Keloid Fibroblasts Requires Cooperativity Between AP-1 and SMAD Binding SitesAnnals of Surgery, 2007
- Differential p63 and p53 Expression in Human Keloid Fibroblasts and Hypertrophic Scar FibroblastsDNA and Cell Biology, 2007
- Upregulation of TGF-β1 Expression May Be Necessary but Is Not Sufficient for Excessive ScarringJournal of Investigative Dermatology, 2006
- P38 MAP kinase mediates transforming growth factor-β2 transcription in human keloid fibroblastsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2006
- Increased transcriptional response to mechanical strain in keloid fibroblasts due to increased focal adhesion complex formationJournal of Cellular Physiology, 2005
- Intralesional 5-fluorouracil in the treatment of keloids: An open clinical and histopathologic studyJournal of the American Academy of Dermatology, 2005
- Role of Transforming Growth Factor β in Human DiseaseNew England Journal of Medicine, 2000
- KELOIDS AND HYPERTROPHIC SCARS: RESULTS WITH INTRA‐OPERATIVE AND SERIAL POSTOPERATIVE CORTICOSTEROID INJECTION THERAPYAnz Journal of Surgery, 1999
- Modulation of Collagen Synthesis by Transforming Growth Factor-β in Keloid and Hypertrophic Scar FibroblastsAnnals of Plastic Surgery, 1994